Sanctuary Advisors LLC Cuts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Sanctuary Advisors LLC trimmed its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 18.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,178 shares of the company’s stock after selling 5,750 shares during the quarter. Sanctuary Advisors LLC’s holdings in Syndax Pharmaceuticals were worth $358,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. State of New Jersey Common Pension Fund D increased its holdings in shares of Syndax Pharmaceuticals by 40.5% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 133,111 shares of the company’s stock valued at $1,760,000 after purchasing an additional 38,339 shares in the last quarter. abrdn plc purchased a new stake in Syndax Pharmaceuticals in the 4th quarter worth $1,313,000. China Universal Asset Management Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company’s stock worth $239,000 after acquiring an additional 1,732 shares in the last quarter. R Squared Ltd purchased a new stake in Syndax Pharmaceuticals in the 4th quarter worth $26,000. Finally, KBC Group NV increased its holdings in Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after acquiring an additional 3,559 shares in the last quarter.

Insider Activity

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the transaction, the chief financial officer now owns 90,746 shares of the company’s stock, valued at $1,406,563. This represents a 4.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. The trade was a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is currently owned by insiders.

Syndax Pharmaceuticals Stock Down 1.0 %

Shares of SNDX opened at $15.48 on Tuesday. Syndax Pharmaceuticals, Inc. has a 52-week low of $12.06 and a 52-week high of $25.16. The firm’s fifty day moving average is $14.23 and its two-hundred day moving average is $16.75. The stock has a market cap of $1.32 billion, a PE ratio of -4.26 and a beta of 0.90.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). As a group, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Ratings Changes

SNDX has been the subject of several recent analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 21st. Scotiabank cut their price target on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. The Goldman Sachs Group boosted their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Citigroup boosted their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. Finally, StockNews.com lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).